|

TOS-358 Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Pipeline

Phase 1: 1

Top Sponsors

  • Totus Medicines1

Indications

  • HR+/HER2-negative Breast Cancer1
  • Squamous Cell Carcinoma of Head and Neck1
  • Endometrial Cancer1
  • Bladder Cancer1
  • Breast Cancer1

Chicago, Illinois1 trial

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Northwestern Memorial Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.